Developer docs
API playgroundTry for free, no card

Search company profiles

Treeline Biosciences

Full company profile

uuid000026t

Namestring
Treeline Biosciences
Legal namestring
Treeline Biosciences, Inc.
Websiteurl
treeline.bio
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology medicines, clinical-stage biopharmaceuticals, protein degrader drug discovery, computational drug discovery, targeted cancer therapies
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Precision Oncology Drug Discovery
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Equity Capital / Venture Financing
TypeSubscription Recurring
Description

Pre-revenue clinical-stage biotech funded almost entirely by private equity. Approximately $1.1B raised cumulatively since 2021, including a $421.78M round in October 2024 and a $200M Series A extension in September 2025; capital is intended to carry multiple programs in parallel rather than milestone-to-milestone.

treeline.bio
2Public Market Capital (Pending Reverse Merger)
TypeSubscription Recurring
Description

Reverse merger with Standard BioTools (NASDAQ: LAB) announced June 6, 2026, injecting ~$450M net cash into Treeline; combined company to trade on Nasdaq as TRLN with over $900M pro-forma cash funding operations into 2029. No product revenue; capital formation is the revenue model until commercialization.

ainvest.com
3Future Out-licensing / Pharma Partnerships (Pipeline)
TypeLicensing Royalties
Description

Pipeine supports future co-development, cost- and risk-sharing partnerships with pharma and financial partners per the Mandate page. In-license of SHR2554 from Jiangsu Hengrui (inbound licensing) demonstrates the company already operates licensing structures; commercialization of approved drugs would be the eventual product revenue stream.

treeline.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1TLN-121
Description

Investigational BCL6 protein degrader (Phase 1) for B-cell and T-cell lymphomas.

treeline.bio
+2 more records
Core offering1 text field

Treeline Biosciences is a clinical-stage biopharmaceutical company that designs and develops precision oncology drug candidates using an integrated in-house discovery platform combining wet-lab research with cloud-first computational and machine learning tools. The company currently has three investigational programs in Phase 1 clinical trials: TLN-121 (BCL6 protein degrader for B-cell and T-cell lymphomas), TLN-254 (EZH2 inhibitor for peripheral and cutaneous T-cell lymphoma), and TLN-372 (pan-KRAS inhibitor for KRAS-altered solid tumors). Pre-revenue with no commercial products, Treeline's therapies are accessible only via clinical trial enrollment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • ~$1.1 billion in capital raised since 2021 founding
+4 more records
Product overview1 text field

Treeline Biosciences operates a single, integrated, target-centric drug discovery platform — the Treeline Discovery Platform — that combines wet-lab R&D at U.S. (Watertown, MA; San Diego, CA) and EU (Basel, Switzerland) facilities with a cloud-first computational platform. The platform is organized around three proven drug-modality toolkits (Oral Small Molecules, Protein Degraders and Glues, and Targeted Therapy Antibody Drug Conjugates/TT-ADCs) and feeds a clinical-stage pipeline of named investigational medicines: TLN-121 (BCL6 degrader, Phase 1, B-cell and T-cell lymphomas), TLN-254 (EZH2 inhibitor in-licensed from Jiangsu Hengrui, Phase 1, peripheral and cutaneous T-cell lymphoma), and TLN-372 (pan-KRAS inhibitor, Phase 1, solid tumors). Treeline's mission is to match compelling disease targets to the best drug approach to deliver category-defining medicines for cancer, autoimmune, and neurological diseases.

Product and service3 records
1TLN-121
CategoryInvestigational oncology drug candidate (protein degrader)
Description

Investigational BCL6-targeted protein degrader in Phase 1 clinical development for B-cell and T-cell lymphomas, designed to selectively remove the BCL6 protein from lymphoma cells while avoiding other targets that could cause toxicity. Listed on ClinicalTrials.gov as NCT07082803.

2TLN-254
CategoryInvestigational oncology drug candidate (small molecule inhibitor)
Description

Investigational EZH2 inhibitor in Phase 1 clinical development for peripheral T-cell lymphoma and cutaneous T-cell lymphoma. In-licensed from Jiangsu Hengrui Pharmaceuticals (SHR2554) for territories outside China, where the medicine holds conditional approval for relapsed/refractory peripheral T-cell lymphoma. Listed on ClinicalTrials.gov as NCT06733441.

3TLN-372
CategoryInvestigational oncology drug candidate (small molecule inhibitor)
Description

Investigational pan-KRAS inhibitor in Phase 1 clinical development for solid tumors, designed from first principles to provide deep and constant pan-KRAS target inhibition across KRAS subsets beyond G12C (where FDA-approved medicines exist). Listed on ClinicalTrials.gov as NCT07204340.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing RAS(ON) inhibitors including a pan-RAS program. Direct comparator to Treeline's pan-KRAS inhibitor TLN-372 and a leading benchmark for KRAS competitive dynamics.

TypeDirect peer
Description

Pioneer in targeted protein degradation (PROTAC degraders) with clinical-stage oncology assets including BCL6-directed programs. Closest direct competitor to Treeline's BCL6 degrader TLN-121 and to its protein-degrader modality toolkit.

TypeDirect peer
Description

Clinical-stage company developing novel small-molecule protein degraders across oncology and immunology. Directly comparable to Treeline's protein-degrader/glue modality and target-centric discovery approach.

TypeDirect peer
Description

Clinical-stage precision oncology company focused on chromatin biology and dysregulated gene expression, including EZH2 programs. Directly comparable to Treeline's TLN-254 EZH2 inhibitor in T-cell lymphoma.

TypeDirect peer
Description

Clinical-stage precision oncology company using motion-based drug design with deep computational and structural biology capabilities. Comparable target-centric, compute-integrated discovery model with clinical oncology assets.

TypeEmerging player
Description

AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning across multiple therapeutic areas. Comparable compute-first, multi-modality platform approach, though broader in therapeutic scope than Treeline.

TypeEmerging player
Description

Generative biology platform company using ML to design novel protein therapeutics. Comparable integration of cloud compute, proprietary data, and ML-driven molecular design, with overlapping modality ambitions in oncology.

TypeEmerging player
Description

ML-driven drug discovery company combining high-throughput biology with proprietary machine learning models. Comparable compute-first, data-flywheel discovery paradigm but focused on metabolic and neurological disease rather than oncology.

TypeDirect peer
Description

Clinical-stage precision oncology company targeting allosteric mutations on oncogenes, including KRAS. Comparable target-centric discovery model and clinical-stage oncology pipeline with multiple kinase/KRAS programs.

TypeEmerging player
Description

Clinical-stage precision oncology company using synthetic lethality and DNA damage response approaches. Comparable target-centric clinical-stage oncology biotech with a multi-asset platform model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Treeline Biosciences

Precision Oncology Drug Discoverytreeline.bio

Treeline Biosciences firmographics

Firmographics
Name
Treeline Biosciences
Legal name
Treeline Biosciences, Inc.
Website
https://treeline.bio
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Treeline Biosciences industry classification

Industry
Product category
Precision Oncology Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision oncology medicines
  • Clinical-stage biopharmaceuticals
  • Protein degrader drug discovery
  • Computational drug discovery
  • Targeted cancer therapies

Where Treeline Biosciences is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Treeline Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Equity Capital / Venture Financing: Pre-revenue clinical-stage biotech funded almost entirely by private equity. Approximately $1.1B raised cumulatively since 2021, including a $421.78M round in October 2024 and a $200M Series A extension in September 2025; capital is intended to carry multiple programs in parallel rather than milestone-to-milestone.
  2. Public Market Capital (Pending Reverse Merger): Reverse merger with Standard BioTools (NASDAQ: LAB) announced June 6, 2026, injecting ~$450M net cash into Treeline; combined company to trade on Nasdaq as TRLN with over $900M pro-forma cash funding operations into 2029. No product revenue; capital formation is the revenue model until commercialization.
  3. Future Out-licensing / Pharma Partnerships (Pipeline): Pipeine supports future co-development, cost- and risk-sharing partnerships with pharma and financial partners per the Mandate page. In-license of SHR2554 from Jiangsu Hengrui (inbound licensing) demonstrates the company already operates licensing structures; commercialization of approved drugs would be the eventual product revenue stream.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Treeline Biosciences product offering

Product offering

Core offering

Treeline Biosciences is a clinical-stage biopharmaceutical company that designs and develops precision oncology drug candidates using an integrated in-house discovery platform combining wet-lab research with cloud-first computational and machine learning tools. The company currently has three investigational programs in Phase 1 clinical trials: TLN-121 (BCL6 protein degrader for B-cell and T-cell lymphomas), TLN-254 (EZH2 inhibitor for peripheral and cutaneous T-cell lymphoma), and TLN-372 (pan-KRAS inhibitor for KRAS-altered solid tumors). Pre-revenue with no commercial products, Treeline's therapies are accessible only via clinical trial enrollment.

Product overview

Treeline Biosciences operates a single, integrated, target-centric drug discovery platform — the Treeline Discovery Platform — that combines wet-lab R&D at U.S. (Watertown, MA; San Diego, CA) and EU (Basel, Switzerland) facilities with a cloud-first computational platform. The platform is organized around three proven drug-modality toolkits (Oral Small Molecules, Protein Degraders and Glues, and Targeted Therapy Antibody Drug Conjugates/TT-ADCs) and feeds a clinical-stage pipeline of named investigational medicines: TLN-121 (BCL6 degrader, Phase 1, B-cell and T-cell lymphomas), TLN-254 (EZH2 inhibitor in-licensed from Jiangsu Hengrui, Phase 1, peripheral and cutaneous T-cell lymphoma), and TLN-372 (pan-KRAS inhibitor, Phase 1, solid tumors). Treeline's mission is to match compelling disease targets to the best drug approach to deliver category-defining medicines for cancer, autoimmune, and neurological diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • TLN-121: Investigational BCL6 protein degrader (Phase 1) for B-cell and T-cell lymphomas.
  • TLN-254
  • TLN-372

Products and services

  • TLN-121 Investigational BCL6-targeted protein degrader in Phase 1 clinical development for B-cell and T-cell lymphomas, designed to selectively remove the BCL6 protein from lymphoma cells while avoiding other targets that could cause toxicity. Listed on ClinicalTrials.gov as NCT07082803.
  • TLN-254 Investigational EZH2 inhibitor in Phase 1 clinical development for peripheral T-cell lymphoma and cutaneous T-cell lymphoma. In-licensed from Jiangsu Hengrui Pharmaceuticals (SHR2554) for territories outside China, where the medicine holds conditional approval for relapsed/refractory peripheral T-cell lymphoma. Listed on ClinicalTrials.gov as NCT06733441.
  • TLN-372 Investigational pan-KRAS inhibitor in Phase 1 clinical development for solid tumors, designed from first principles to provide deep and constant pan-KRAS target inhibition across KRAS subsets beyond G12C (where FDA-approved medicines exist). Listed on ClinicalTrials.gov as NCT07204340.

Quantifiable outcome

  • ~$1.1 billion in capital raised since 2021 founding
  • +4 more outcomes

Companies that use Treeline Biosciences

Customer profile

Segments5 records

Ideal customer profiles3 records

Treeline Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Treeline Biosciences partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Treeline Biosciences competitors and assessment

Company assessment

Direct peers

  • Revolution Medicines: Clinical-stage precision oncology company developing RAS(ON) inhibitors including a pan-RAS program. Direct comparator to Treeline's pan-KRAS inhibitor TLN-372 and a leading benchmark for KRAS competitive dynamics.
  • Arvinas: Pioneer in targeted protein degradation (PROTAC degraders) with clinical-stage oncology assets including BCL6-directed programs. Closest direct competitor to Treeline's BCL6 degrader TLN-121 and to its protein-degrader modality toolkit.
  • Kymera Therapeutics: Clinical-stage company developing novel small-molecule protein degraders across oncology and immunology. Directly comparable to Treeline's protein-degrader/glue modality and target-centric discovery approach.
  • Foghorn Therapeutics: Clinical-stage precision oncology company focused on chromatin biology and dysregulated gene expression, including EZH2 programs. Directly comparable to Treeline's TLN-254 EZH2 inhibitor in T-cell lymphoma.
  • Relay Therapeutics: Clinical-stage precision oncology company using motion-based drug design with deep computational and structural biology capabilities. Comparable target-centric, compute-integrated discovery model with clinical oncology assets.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company targeting allosteric mutations on oncogenes, including KRAS. Comparable target-centric discovery model and clinical-stage oncology pipeline with multiple kinase/KRAS programs.

Emerging players

  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning across multiple therapeutic areas. Comparable compute-first, multi-modality platform approach, though broader in therapeutic scope than Treeline.
  • Generate Biomedicines: Generative biology platform company using ML to design novel protein therapeutics. Comparable integration of cloud compute, proprietary data, and ML-driven molecular design, with overlapping modality ambitions in oncology.
  • Insitro: ML-driven drug discovery company combining high-throughput biology with proprietary machine learning models. Comparable compute-first, data-flywheel discovery paradigm but focused on metabolic and neurological disease rather than oncology.
  • Tango Therapeutics: Clinical-stage precision oncology company using synthetic lethality and DNA damage response approaches. Comparable target-centric clinical-stage oncology biotech with a multi-asset platform model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Treeline Biosciences compliance and trust

Trust signal

Compliance3 records

Treeline Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Treeline Biosciences leadership team

Management profile

Number of profiles

Profiles4 records

Treeline Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Treeline Biosciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Treeline Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Treeline Biosciences

What does Treeline Biosciences do?

Treeline Biosciences is a clinical-stage biopharmaceutical company that designs and develops precision oncology drug candidates using an integrated in-house discovery platform combining wet-lab research with cloud-first computational and machine learning tools. The company currently has three investigational programs in Phase 1 clinical trials: TLN-121 (BCL6 protein degrader for B-cell and T-cell lymphomas), TLN-254 (EZH2 inhibitor for peripheral and cutaneous T-cell lymphoma), and TLN-372 (pan-KRAS inhibitor for KRAS-altered solid tumors). Pre-revenue with no commercial products, Treeline's therapies are accessible only via clinical trial enrollment.

Is Treeline Biosciences a public or private company?

Treeline Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Treeline Biosciences founded?

Treeline Biosciences was founded in 2021. It employs 101 to 250 people.

Where is Treeline Biosciences based?

Treeline Biosciences is headquartered in Watertown, United States, in the North America region.

How does Treeline Biosciences make money?

Three revenue lines are on record. Equity Capital / Venture Financing is the primary driver. The others are public Market Capital (Pending Reverse Merger) and future Out-licensing / Pharma Partnerships (Pipeline).

Who are Treeline Biosciences's main competitors?

Direct peers on record are Revolution Medicines, Arvinas, Kymera Therapeutics, Foghorn Therapeutics, Relay Therapeutics and Black Diamond Therapeutics. Emerging players are Recursion Pharmaceuticals, Generate Biomedicines, Insitro and Tango Therapeutics.

Does Treeline Biosciences have an API?

No public API is recorded for Treeline Biosciences.

What industry is Treeline Biosciences in?

Treeline Biosciences's product category is Precision Oncology Drug Discovery. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceStandard BioTools Provides Update on Sale of Mass Cytometry BusinessStandard BioTools terminated its agreement to sell its Mass Cytometry business to Multiplex Bio and entered a definitive agreement to sell it to Element Biosystems, a GMT Venture subsidiary, for $5.5 million in cash. The upfront cash increases the net cash position by approximately $15 million after fees, and the Element transaction is expected to close by the end of 2026.AInvestLAB Stock Faces Investor Scrutiny Amid Proposed Treeline Biosciences MergerHalper Sadeh LLC is investigating Standard BioTools' proposed merger with Treeline Biosciences for potential fiduciary breaches and inadequate shareholder compensation. The company trades at a 3.14 P/E ratio, well below the healthcare sector average, while institutional investors hold 53.74% of shares. The investigation could delay or alter the deal, with shareholders receiving 16% of the combined entity.AInvestLAB Faces Scrutiny Over Merger Deal Structure and Valuation MetricsHalper Sadeh LLC is investigating Standard BioTools' merger with Treeline Biosciences, alleging fiduciary breaches and insider favoritism. The deal leaves Standard BioTools shareholders with only 16% ownership, and the stock trades at a 3.14 P/E ratio versus a sector average of 273.26. Legal proceedings are on a contingent fee basis.MorningstarAre SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?Halper Sadeh LLC is investigating Sanara MedTech, Standard BioTools, Atkore, and Valaris for potential securities law violations and fiduciary breaches in their proposed deals. The firm may seek increased consideration or additional disclosures on a contingent fee basis.Gurufocus$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the PrMonteverde & Associates PC, a class action securities firm, is investigating four shareholder proxy votes: VerifyMe's merger with Open World, Valaris's sale to Transocean, Standard Biotools's merger with Treeline Biosciences, and Fathom Holdings's sale to Bed Bath & Beyond. The firm highlights its track record of recovering millions for shareholders and invites affected shareholders to seek free information.MorningstarINVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger—IRDM, VRME, VAL and LABMonteverde & Associates PC, a securities class action firm, announced it is investigating four companies' mergers: Iridium Communications, VerifyMe, Valaris, and Standard Biotools. The firm highlights its track record of recovering millions for shareholders and invites investors to contact it for free information.PR NewswireINVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LABMonteverde & Associates PC, a class action securities firm, is investigating four merger-related transactions: Iridium Communications' sale to Rocket Lab, VerifyMe's merger with Open World, Valaris' sale to Transocean, and Standard Biotools' merger with Treeline Biosciences. The firm states it has recovered millions for shareholders and invites investors to contact it for free information.BioWorldTreeline Biosciences reports new KRAS degraders and inhibitorsTreeline Biosciences Inc. has patented GTPase KRAS degraders and inhibitors designed for cancer treatment. The patents cover compounds that target KRAS, a key driver in many cancers. No further details on the compounds or clinical status were disclosed.Clinical Trials ArenaTreeline and Roche collaborate on TLN-121 combo trial for BCLTreeline Biosciences and Roche signed a Phase I trial collaboration to test TLN-121 with glofitamab and mosunetuzumab in B-cell lymphomas. Treeline will sponsor and oversee the study, with Roche supplying the antibodies, and combination dosing is planned for Q4 2026.The Pharma LetterTreeline Biosciences enters clinical trial collaboration with RocheTreeline Biosciences announced a clinical trial collaboration with Roche to evaluate its BCL6 degrader TLN-121 in combination with Roche's glofitamab and mosunetuzumab for B-cell lymphomas, including diffuse large B-cell lymphoma. The drug will be tested in separate combination cohorts.